Pioneers in Immunotherapy | Change a Life

Only 4% of federal funding for cancer research is directed toward children’s cancers. As a result, children are often given adult cancer treatment options, which frequently leads to toxic and long-term side effects.
MSK Kids at Memorial Sloan Kettering is leading breakthrough research in immunotherapies, which are targeted and less toxic treatments that harness a patient’s own immune system to fight cancer.
These life-saving therapies have not only helped extend the quality of life and survival rates for kids, but they are also being used to treat some adult cancers.
As part of its longstanding commitment to help kids lead healthy lives, RBC Capital Markets directs all fundraising in support of MSK Kids to fund immunotherapy research. Discover more about our partnership: spr.ly/6059Mmxev
Learn more about MSK Kids: spr.ly/6050Mmxea
Learn more about immunotherapy at Memorial Sloan Kettering: spr.ly/6051Mmxex
About RBC Capital Markets - An Innovative, Trusted Partner
RBC Capital Markets is recognized by the most significant corporations, institutional investors, asset managers, private equity firms, and governments around the globe as an innovative, trusted partner with an in-depth expertise in capital markets, banking, and finance.
We are well-established in the largest, most mature capital markets across North America, Europe, and the Asia-Pacific region, which collectively encompass more than 75% of global investment banking activity each year.
About Royal Bank of Canada
We are part of Royal Bank of Canada (RBC), a leading, diversified provider of financial services and one of the strongest banks globally. Founded in 1864, RBC is the 10th largest bank worldwide and the 5th in North America, as measured by market capitalization.
RBC is among a small group of highly rated global banks and is recognized time and time again for its financial strength, market leadership and philanthropic work.
For information on our legal terms of use visit: spr.ly/6050GGRH2